MaxCyte Signs Strategic Platform License with Lyell Immunopharma
July 06 2023 - 8:05AM
MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading,
cell-engineering focused company providing enabling platform
technologies to advance the discovery, development and
commercialization of next-generation cell-based therapeutics and to
support innovative, cell-based research, today announced the
signing of a strategic platform license (SPL) with Lyell
Immunopharma, Inc., a clinical stage T cell reprogramming company.
Under the terms of the agreement, Lyell Immunopharma obtains
non-exclusive clinical and commercial rights to use MaxCyte’s Flow
Electroporation® technology and ExPERT™ platform. In return,
MaxCyte is eligible to receive platform licensing fees, clinical
milestone payments and sales-based payments.
“At MaxCyte, our goal is to maximize the potential of cells to
improve patients’ lives, and it is through collaborations such as
this that we can achieve success,” said Doug Doerfler,
President and CEO of MaxCyte. “We look forward to
supporting Lyell Immunopharma in its development of solid tumor
treatments for patients with unmet needs.”
MaxCyte’s ExPERT™ instrument portfolio is the next generation of
leading, clinically-validated electroporation technology for
complex and scalable cell engineering. By delivering high
transfection efficiency, seamless scalability and enhanced
functionality, the ExPERT™ platform delivers the high-end
performance essential to enabling the next wave of biological and
cellular therapeutics. Each of MaxCyte’s strategic partnerships
generates pre-commercial milestone revenue and the vast majority
include sales-based payments.
About MaxCyte At MaxCyte, we pursue cell
engineering excellence to maximize the potential of cells to
improve patients’ lives. We have spent more than 20 years honing
our expertise by building best-in-class platforms, perfecting the
art of the transfection workflow, and venturing beyond today’s
processes to innovate tomorrow’s solutions. Our ExPERT™ platform,
which is based on our Flow Electroporation® technology, has been
designed to support the rapidly expanding cell therapy market and
can be utilized across the continuum of the high-growth cell
therapy sector, from discovery and development through
commercialization of next-generation, cell-based medicines. The
ExPERT family of products includes: four instruments, the ATx™,
STx™, GTx™ and VLx ™; a portfolio of proprietary related processing
assemblies or disposables; and software protocols, all supported by
a robust worldwide intellectual property portfolio. By providing
our partners with the right technology, as well as technical and
regulatory support, we aim to guide them on their journey to
transform human health. Learn more at maxcyte.com and follow us on
Twitter and LinkedIn.
MaxCyte Contacts:
US IR Adviser Gilmartin
Group David Deuchler, CFA +1
415-937-5400 ir@maxcyte.com
US Media Relations Spectrum
Seismic Collaborative Valerie Enes +1
408-497-8568 valerie@spectrumscience.com
Nominated Adviser and Joint Corporate
Broker Panmure Gordon Emma Earl / Freddy
Crossley Corporate Broking Rupert Dearden +44 (0)20
7886 2500
UK IR Adviser Consilium Strategic
Communications Mary-Jane Elliott Chris
Welsh +44 (0)203 709
5700 maxcyte@consilium-comms.com
MaxCyte (NASDAQ:MXCT)
Historical Stock Chart
From Apr 2024 to May 2024
MaxCyte (NASDAQ:MXCT)
Historical Stock Chart
From May 2023 to May 2024